Skip to main content
Top

Harnessing hematological ratios: prognostic insights for breast cancer management

Published in:

Abstract

Background

Breast cancer is one of the most lethal diseases affecting women globally. Its progression is influenced by various factors, including the immune system's ability to combat cancer cells. While hematological indices have been recognized as valuable biomarkers for monitoring patients with different types of neoplasms, there remains a considerable gap in research concerning their application in breast cancer.

Material and Methods

To address this, we conducted a systematic review of studies examining hematological indices as prognostic predictors in breast cancer patients.

Results

The majority of studies demonstrate a significant correlation between these indices and survival outcomes, underscoring their potential utility in patient monitoring.

Conclusions

Hematological-based indexes can be valuable tools for monitoring breast cancer, especially those ongoing poor prognosis scenarios.
Title
Harnessing hematological ratios: prognostic insights for breast cancer management
Authors
Carolina Coradi
Carolina Panis
Publication date
14-10-2024
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 5/2025
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-024-03721-z
This content is only visible if you are logged in and have the appropriate permissions.

2025 ESMO Congress hub

Unlock your free and exclusive access to expert interviews, news, and more from the annual congress of the European Society for Medical Oncology.

Read more

Keynote webinar | Spotlight on progress in colorectal cancer

  • Live
  • Webinar | 11-12-2025 | 18:00 (CET)

CRC remains a major global health burden, but advances in screening, treatment, and lifestyle-based prevention continue to reshape clinical practice. Gain insights into how the latest research can be leveraged to optimize patient care across the CRC continuum.

Watch it live: Thursday 11 December 2025, 18:00-19:30 (CET)

Prof. Antoni Castells
Prof. Edward Giovannucci
Developed by: Springer Medicine
Join the webinar
Webinar

Are you up to date on targeted therapies for relapsed/refractory AML? 

Join Prof. Amer Zeidan and his expert guests to hear about innovations in molecular testing, emerging therapies, and IDH-targeted treatments, and get practical advice for improving your patient care.

Supported by: independent educational grant from Rigel

Find out more
Image Credits
Cancer cell screening and treatment concept/© artacet / iStock / Getty Images Plus, Colon cancer illustration/© (M) KATERYNA KON/SCIENCE PHOTO LIBRARY / Getty Images